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1. Introduction: Platelet-rich plasma (PRP) is blood plasma with a high concentration of autologous platelets which constitute an immense 
reservoir of growth factors. The clinical use of PRP is widespread in various medical applications. Although highly popular with athletes, the 
use of PRP for the treatment of tendinopathies remains scientifically controversial, particularly due to the diversity of products that go by the 
name of “PRP”. This may partly explain the disparity of results obtained in the literature. 
2. Purpose: The objective of this study was to evaluate the similarities 
and differences between the variety of PRP formulations, preparation, 
and uses of this techniques in literature and to try to determine 
characteristics of the PRP which tend to give the best responses for the 
treatment of knee osteoarthritis. 
3. Methods: A search for articles was conducted in the Pubmed and 
Pedro databases. The results were obtained by using the following key 
words and combinations of these key words: PRP, platelet-rich plasma, 
injection, treatment, tennis elbow, greater trochanteric pain syndrome, 
jumper’s knee, Achilles tendinopathy, plantar fasciitis, anticoagulant, 
sodium chloride, local anesthetic, and centrifugation speed. 
In this literature review, we take a closer look at eight parameters which 
may influence the quality of PRP: 1) anticoagulants used to preserve 
the best platelet function, 2) the speed of centrifugation used to extract 
the platelets, 3) the platelet concentrations obtained, 4) the impact of 
the concentration of red and while blood cells on PRP actions, 5) 
platelet activators encouraging platelet degranulation and, hence, the 
release of growth factors, and 6) the use or nonuse of local anesthetics 
when carrying out infiltration. In addition to these parameters, it may 
be interesting to analyze other variables such as 7) the use of 
ultrasound guidance during the injection with a view to determining 
the influence they have on potential recovery. 
4. Results: Analysis of the 59 studies shows that a majority use 
ACDA as an anticoagulant during sampling. A platelet activator 
(calcium chloride) is only used in a few studies. However, the best 
results have been obtained in studies which use no platelet 
activator. In terms of the speed of centrifugation, analysis of all 
these studies appears to confirm the existence of a great number 
of protocols in the literature. It is difficult to draw any conclusions 
when these different variables are unknown (volume of initial 
sample, equipment used to obtain the PRP). Currently, no studies 
have been carried out neither on the use of a “buffer” product to 
neutralize the acidity caused by the anticoagulant nor on the 
optimal volume of PRP to be injected. Although it would appear 
inadvisable to administer a local anesthetic because the 
anesthetic may reduce the local pH and lead to the inhibition, 
reduction, or absence of platelet degranulation, the literature 
shows that the majority use a local anesthetic. They do not, 
however, obtain better results than those not using a local 
anesthetic. Finally, it appears to be advisable to carry out 
infiltration under ultrasound guidance, even if PRP diffusion is 
observed after injection. This all aims to show that there is still a 
need for high quality studies, with standardized collection 
protocols and the use of PRP in the context of tendinopathies, in 
order to better scientifically understand the real effectiveness. 
5. Conclusions: Although there is an increasing amount of scientific proof about the benefits of PRP infiltration in the treatment of 
tendinopathies, there is currently no consensus as to how to obtain or use it. This may partly explain the disparity of results obtained in the 
literature. Similarly, the biological parameters and risk factors for tendinopathies of patients themselves may possibly influence the results of 
this treatment even if, to date, this has not yet been demonstrated. There is a lack of standardization in PRP preparation technique for chronic 
tendinopathies. However, our study helped identify features of PRP recommended a platelet concentration lower than 5 times the baseline 
(from 3 to 4), and avoiding leukocytes and erythrocytes. We recommend leveraging this information about PRP for future studies. 
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